Stanford University researchers study concludes that clinical trials can offer patients with Huntington’s disease (HD) hope when there are no treatments available despite unknowns whether the therapy will work or is safe. The study results show that although the HD...
The Alzheimer’s Drug Discovery Foundation (ADDF) has granted an award, in the form of an investment of up to approximately $3 million in Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and...
Researchers from the Center for Neurogenetics and colleagues from the Northwestern University Feinberg School of Medicine report a novel small-molecule modulator called S-181 shows promise in preclinical research animal studies for the treatment of a familial form of...
The Alzheimer’s Drug Discovery Foundation (ADDF) has invested $6 million in six investments via its Diagnostics Accelerator initiative. Specific research awards include studies involving blood tests in various stages of development including one that could become a...
A new University of Toronto study highlights how protein strains vary in the brains of those affected by progressive neurodegenerative diseases such as Parkinson’s suggesting a growing recognition of the need for patient-specific medicines. Published in...
Singapore-based TauRX is progressing its experimental medicine known as “LMTM” to advanced Phase III clinical trials in America and Europe based on the results of two previous Phase III studies evidencing the potential promise as a treatment for Alzheimer’s disease....
